On Friday, Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House.

Makers of the top selling drugs in the United States are costing patients billions of dollars and worsening a drug pricing crisis by abusing the U.S. patent system to stifle competition and inflate prices, a consumer group said on Thursday,

Non-small cell lung cancer (NSCLC) was a hot topic at the recent European Society for Medical Oncology (ESMO) Congress, where several researchers presented landmark findings, many of which are considered to be firsts. Such results portend advances that could significantly improve survival for patients with this common form of cancer.

Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company said.

Amgen announced Tuesday morning that its initial Phase III data of its oral drug Lumakras (sotorasib) met its primary endpoint of progression-free survival in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).

The U.S. Senate Finance Committee is widening its investigation into the tax practices of U.S. drugmakers to include Amgen Inc (AMGN.O), according to a letter sent on Thursday by the committee’s chairman, Senator Ron Wyden.

While the economy expands and contracts, the biopharma industry follows, and many life science companies are announcing both layoffs and expansions.

A small study of Amgen Inc.’s Lumakras drug combined with immunotherapy found it helped 29% of advanced lung cancer patients, but liver toxicity was high and further study is needed, the company said ahead of the data presentation on Sunday at the World Conference on Lung Cancer in Vienna.

Shares of ChemoCentryx are skyrocketing in premarket trading after the company announced it will be acquired by Amgen in a $4 billion deal that will bring Tavneos, a first-in-class treatment for ANCA-associated vasculitis, into the company’s portfolio.

The U.S. Attorney’s Office for the Southern District of New York was busy yesterday, indicting nine people for charges related to insider trading. The specific charges were unrelated to each other, but some were specific to the biopharma industry. Read on for details.